Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.
Xenetic Biosciences reports developments tied to its immuno-oncology programs for difficult-to-treat cancers. The company’s DNase technology targets neutrophil extracellular traps, or NETs, with a systemic DNase program being advanced as an adjunctive approach for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Recurring updates include preclinical and translational research, conference presentations, collaborations with institutional and development partners, and studies evaluating DNase I with chemotherapy, immunotherapies and CAR T-cell approaches. Company news also covers periodic financial results, cash resources, equity financing, shareholder voting matters and other governance developments.
Xenetic Biosciences (NASDAQ: XBIO) reported first quarter 2026 results and progress on its DNase I oncology platform. Royalty revenue rose about 36% to $0.8 million, while research and development and general and administrative expenses declined.
Net loss fell to $0.5 million, with $7.3 million in cash as the company evaluates strategic alternatives.
Xenetic Biosciences (NASDAQ:XBIO) announced an abstract acceptance for presentation at the 2026 ASCO Annual Meeting, May 29–June 2, 2026, in Chicago.
The poster, titled "Targeting cfDNA and NETs with DNase I to augment CAR T cell function and antitumor efficacy," will be presented June 1, 2026, 9:00 AM–12:00 PM CDT (Poster Board 410) by Alexey V. Stepanov, PhD, in the Hematologic Malignancies - Plasma Cell Dyscrasia session.
Xenetic Biosciences (NASDAQ:XBIO) reported full-year 2025 results and scientific progress on its DNase I immuno-oncology program. Key points: net loss of $2.7 million, royalty revenue up ~19% to $3.0 million, and year-end cash of $7.9 million. The company advanced preclinical, translational and IND-enabling activities and supported investigator-initiated trials in PDAC and proposed LBCL/CAR-T combinations.
Xenetic Biosciences (NASDAQ:XBIO) announced its 2025 Annual Meeting of Stockholders was convened and adjourned on December 11, 2025 due to a lack of quorum.
The meeting will reconvene virtually at 10:00 a.m. ET on Thursday, January 8, 2026. The record date for voting remains October 15, 2025. Stockholders who already voted do not need to re-submit votes; previously submitted proxies remain valid unless revoked.
Stockholders who have not voted are urged to vote by 11:59 p.m. ET on January 7, 2026 via www.proxyvote.com or telephone 1-800-690-6903. Broker-held shares may have earlier deadlines. The reconvened meeting can be attended at http://www.virtualshareholdermeeting.com/XBIO2025.
Xenetic Biosciences (NASDAQ:XBIO) executed a 4-month extension of its R&D collaboration with Scripps Research and Dr. Alexey Stepanov effective November 1, 2025 to advance its systemic DNase I program (XBIO-015) in combination with CAR-T therapies.
Preclinical studies in lymphoma, metastatic melanoma and leukemia models reported that co-administration of DNase I with CAR-T cells reduced tumor burden, decreased metastatic lesions, increased CAR-T and endogenous T-cell tumor infiltration, and extended survival versus CAR-T monotherapy. Xenetic says the program has progressed from proof-of-concept to mechanism-of-action and translational studies in preparation for a Phase 1 clinical trial targeting pancreatic carcinoma and other advanced solid tumors.
Xenetic Biosciences (NASDAQ:XBIO) reported third quarter 2025 results on November 13, 2025, highlighting continued preclinical progress on its systemic DNase I oncology program and partnerships to support investigator‑initiated studies.
Key financials: Q3 net loss ~$0.5M; R&D +105.6% to ~$0.8M; Revenue +67.2% to ~$1.0M driven by Takeda sublicense royalties; quarter‑end cash ~$4.1M and subsequent October 2025 underwritten offering net proceeds of ~$3.9M to extend runway toward IND preparation and Phase 1 initiation.
Xenetic Biosciences (NASDAQ:XBIO) priced an underwritten offering of 735,000 shares of common stock at $6.12 per share for gross proceeds of approximately $4.5 million. The offering is expected to close on or about October 14, 2025, subject to customary closing conditions, with Canaccord Genuity as sole bookrunner.
All shares are being offered by Xenetic and proceeds are intended for working capital and general corporate purposes. The offering is made under a Form S-3 shelf registration declared effective November 1, 2024 (File No. 333-282756); a final prospectus supplement will be filed with the SEC.
Xenetic Biosciences (NASDAQ:XBIO) reported its Q2 2025 financial results, highlighting key developments in its immuno-oncology programs. The company has expanded its strategic partnership with The Scripps Research Institute to advance DNase I combination therapy with CAR T-cells. Through collaboration with PeriNess, Xenetic initiated clinical studies exploring DNase I combinations with anti-CD19 CAR T cells for lymphoma and with FOLFIRINOX for pancreatic cancer.
Financial results showed a net loss of $0.7 million for Q2 2025, with decreased R&D expenses of $0.7 million (down 29.7% YoY) and reduced G&A expenses of $0.7 million (down 41.8% YoY). The company maintained a cash position of $4.8 million at quarter-end.
Xenetic Biosciences (NASDAQ:XBIO) announced that its collaboration partner PeriNess has entered into a Clinical Study Agreement to evaluate DNase I in combination with anti-CD19 CAR T cells for treating large B cell lymphoma. The study will be conducted at Tel Aviv Sourasky Medical Center under Dr. Ron Ram's leadership.
The study aims to assess the safety and efficacy of DNase I as an adjuvant therapy with CAR T treatment. Secondary objectives include measuring complete response rate, duration of response, and overall survival. Preclinical studies have shown that DNase I co-administration with anti-CD19 CAR T cells significantly reduced tumor burden and improved survival compared to CAR T cell monotherapy.
This development follows Xenetic's December 2024 agreement with PeriNess for investigating DNase I as an adjunctive treatment in pancreatic carcinoma and other solid tumors.
Xenetic Biosciences (NASDAQ:XBIO) has expanded its research collaboration with The Scripps Research Institute to advance its DNase platform development. The company's systemic DNase I candidate, XBIO-015, is being developed in combination with CAR-T cell therapy for both hematologic and solid tumors.
Studies have demonstrated that co-administration of DNase I with CAR-T cells significantly reduces tumor burden, decreases metastatic lesions, and extends survival compared to CAR-T cell therapy alone. The research program will now include additional models of lymphoma and leukemia to further validate these findings.
The DNase-based platform targets neutrophil extracellular traps (NETs) in the tumor microenvironment, with preclinical data showing improved efficacy of various cancer treatments. The company is advancing towards Phase 1 clinical development for pancreatic carcinoma and other advanced solid tumors.